Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2008 Mar-Apr;10(2):74-81.
doi: 10.1007/s11307-007-0127-y. Epub 2008 Jan 15.

FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma

Phillip H Kuo  1 , Bruce L McClennan, Kacie Carlson, Lynn D Wilson, Richard L Edelson, Peter W Heald, Michael Girardi
Affiliations
Case Reports

FDG-PET/CT in the evaluation of cutaneous T-cell lymphoma

Phillip H Kuo et al. Mol Imaging Biol. 2008 Mar-Apr.

Abstract

This comprehensive case series illustrates the findings on 2-deoxy-2-[F-18]fluoro-D: -glucose (FDG) positron-emission tomography/computed tomography (PET/CT) of patients with varying stages of cutaneous T-cell lymphoma (CTCL). Patients were imaged with full-body scanning using a General Electric Discovery ST 16-slice PET/CT machine. Patients were assessed by PET/CT for cutaneous, nodal, and solid organ FDG uptake, indicative of highly metabolically active (i.e., putatively malignant cells) disease, and comparisons were made to CT data alone and to the physical examination. Several key observations strongly suggested that information afforded by PET/CT scan may be valuable. Various cutaneous lesions, from thin subtle plaques to thick tumors, were revealed and corresponded accurately to the cutaneous examination. In the case of subcutaneous lesions, PET/CT outperformed physical exam. CT also provided the depth/thickness of lesions. The differing levels of FDG uptake in enlarged nodes found within an individual patient as well as among different patients may potentially distinguish reactive from malignant adenopathy. Additionally, lymph nodes that did not meet staging size criteria (e.g., were not > 1 cm) revealed increased metabolic activity and, therefore, could be targeted for subsequent monitoring or biopsy. In addition, PET/CT identified visceral involvement in cases with advanced disease. In summary, PET/CT can provide physiologic and anatomic information on the wide diversity of external and internal lesions in CTCL and, therefore, may have great potential for improving the staging and monitoring of response to therapy of cutaneous, nodal, and visceral disease.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Radiology. 2004 Sep;232(3):823-9 - PubMed
    1. Front Radiat Ther Oncol. 2006;39:1-15 - PubMed
    1. Mol Imaging Biol. 2004 Nov-Dec;6(6):411-6 - PubMed
    1. Ann Nucl Med. 1994 Aug;8(3):187-91 - PubMed
    1. J Nucl Med. 1992 Mar;33(3):325-9 - PubMed

Publication types

Substances